Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Basic

Trade crypto freely

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart access to new on-chain tokens

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

Access hundreds of perpetual contracts

One platform for global traditional assets

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Stock CFD Derivatives

Access real US stocks and ETFs

Trade quality Hong Kong-listed stocks

Real Korean stocks and top assets

High leverage, 24/7 trading

Tokenized Stocks

Backed by real stock assets

Unlock full access to global stock IPOs

Mint GUSD for Treasury RWA yields

Stocks Activities

Trade Popular Stocks and Unlock Generous Airdrops

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

Earn interest with idle tokens

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Pledge one crypto to borrow another

One-stop lending hub

Limited-Time 4% APR on USDT

Take control of your financial future

Top-tier quant strategies

Stake cryptos to earn in PoS products

No-liquidation leverage

Mint and Redeem Anytime, No Redemption Fees

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

More

Promotions

Activity Center

Participate in activities to earn rewards

Invite friends to earn referral rewards

Affiliate Program

Earn exclusive commission rewards

Grow influence and earn airdrops

Real-time platform updates

Crypto industry articles

Huge fee discounts

Asset Management

One‑stop asset management solution

Enterprise digital asset solutions

Developers (API)

Connects to the Gate application ecosystem

OTC Bank Transfer

Deposit and withdraw fiat

Generous API rebate mechanisms

AI

Your all-in-one conversational AI partner

Use Gate AI directly in your social App

Gate Blue Lobster, ready to go

Gate for AI Agent

AI infrastructure, Gate MCP, Skills, and CLI

Gate Skills Hub

From office tasks to trading, the all-in-one skill hub makes AI even more useful.

Others

Find FAQs and help guides

Learn about crypto investing

Grow with the champions

Proof of Reserves

Gate promises 100% proof of reserves

Keep your assets secure

Eli Lilly Clears Two Obesity Drug Trials, Files for Retatrutide Approval in Q1 2027

2026-07-23 11:28:45

According to Eli Lilly, on Thursday the pharmaceutical company said it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027 after the treatment succeeded in two late-stage trials. In one trial, adults with obesity and diabetes lost an average of 20.8% of body weight (approximately 50 pounds) at 80 weeks. In a second trial, adults with severe obesity and cardiovascular disease lost an average of 22.6% of body weight (approximately 55.8 pounds) at 80 weeks. The company previously planned to submit an application in 2026 but needs additional time to gather manufacturing and quality-control data required by regulators.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

Fed's Asset Sheet May Not Resume Shrinking Until Late 2027, Says TD Securities

Apple Plans Mac Overhaul With M6 Chips, OLED Displays, and New iMac This Fall

Bitcoin Ownership Overtakes Gold as 49.6 Million Americans Now Hold BTC

Trump Plans New Tariffs on Dozens of Nations This Week as 10% Rate Expires Friday

Corning Stock Falls 40% Since June Peak; Morgan Stanley Eyes H2 Optical Capacity Expansion as Recovery Catalyst

In-Depth Analysis

KB Financial Confirms Dividend Cut, Explores ROE-Linked Returns

Lucas Bennett4h ago

EWC MLBB Mid-Season Cup prediction: ONIC has 93% of the funds backing it on the prediction market—can Entity7, with a 10% win rate, pull off an upset?

Gate Instant Trends5h ago

Kolon TissueGene Stocks Hit 3-Day Limit-Down After US Phase 3 Trial Failure

Lucas Bennett5h ago

Comment

0/400

No comments